Evidence map›Paper›PMID 42657369›Full record

ArticleJournal of translational internal medicine2026

Bone marrow mesenchymal stem cells are functionally remodeled after complete remission of acute myeloid leukemia.

Zhiwei Zhang, Zhenkun Wang, Xinyan Zhang, Dandan Chen, Chenyuan Li, Lijuan Hu, Zhengli Xu, Xiaojun Huang, Yuan Kong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhiwei ZhangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China.
Zhenkun WangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China.
Xinyan ZhangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China.
Dandan ChenPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China.
Chenyuan LiPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China.
Lijuan HuPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China.
Zhengli XuPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China.
Xiaojun HuangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China.ORCID https://orcid.org/0000-0002-2145-6643
Yuan KongPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China.ORCID https://orcid.org/0000-0001-5594-2642

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: Acute myeloid leukemia (AML) is a type of hematological malignancy, induces the normal bone marrow (BM) microenvironment to supporting AML cells. Although previous work revealed that functional remodeling of BM endothelial progenitor cells after complete remission (CR), as another important component of the BM microenvironment, whether AML-induced BM mesenchymal stem cells (MSCs) can also be functional modified after CR is largely unknown. Methods: Patients with de novo AML, patients with AML who achieved complete remission (AML-CR) and healthy controls (HC) were enrolled. Flow cytometry was used to exploring the regulatory effects of BM MSCs on cluster of differentiation CD34 Results: Dysfunctional BM MSCs in AML patients were subsequently recovered in AML-CR patients, including their differentiation potential, apoptosis ratio, expression of cytokines and regulatory roles, which were return to near HC MSCs. Moreover, the transcriptomic profile of CR MSCs was also remodeled and transformed to be more similar to that of HC MSCs. Our data further revealed that the expression of senescent-related genes, the number of senescent cells in AML-CR patients were reduced, and that CR MSCs regained the ability to be reinduced to senescence by AML cells. Conclusions: Our findings describe the functional remodeling of BM MSCs among patients with AML, AML-CR patients and HC, and the reduction in the number of senescent BM MSCs associated with BM MSC remodeling. Our work provides a new perspective indicating that AML-modified BM MSCs can be remodeled to support normal hematopoietic stem cells (HSCs) in AML-CR patients, which may contribute to promoting normal hematopoiesis recovery for AML patients.

Indexed as

acute myeloid leukemiacellular senescencechemo-therapyhematopoiesismesenchymal stem cellsremodel

Identifiers

PMID42657369
PMCPMC13509149

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.